<div class="container">

<table style="width: 100%;"><tr>
<td>esophagus</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>SAKK Esophagus Cancer Data</h2>

<h3>Description</h3>

<p>This anonymized data contains survival data from patients with resectable esophageal carcinoma
to compare the outcomes of two treatment regimens: Neoadjuvant chemotherapy
followed by chemoradiation and surgery with and without cetuximab.
</p>


<h3>Usage</h3>

<pre><code class="language-R">esophagus
</code></pre>


<h3>Format</h3>

<p>A data frame with 297 patients and 6 variables:
</p>

<dl>
<dt>arm</dt>
<dd>
<p>Treatment Arm.</p>
</dd>
<dt>OS.time</dt>
<dd>
<p>Overall survival time in years.</p>
</dd>
<dt>OS.event</dt>
<dd>
<p>Overall survival status (0 = censored, 1 = event).</p>
</dd>
<dt>hist</dt>
<dd>
<p>Histological type of the tumor.</p>
</dd>
<dt>PFS.time</dt>
<dd>
<p>Progression-free survival time in years.</p>
</dd>
<dt>PFS.event</dt>
<dd>
<p>Progression-free survival status (0 = censored, 1 = event).</p>
</dd>
</dl>
<h3>Source</h3>

<p>SAKK Competence Center, Switzerland
</p>


<h3>References</h3>

<p>Ruhstaller, T., Thuss-Patience, P., Hayoz, S., Schacher, S., Knorrenschild, J. R., Schnider, A., ... &amp; Stahl, M. (2018). Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Annals of oncology, 29(6), 1386-1393.
</p>


</div>